Aclaris Therapeutics Files 8-K with Corporate Governance Updates
Ticker: ACRS · Form: 8-K · Filed: Jun 5, 2025 · CIK: 1557746
| Field | Detail |
|---|---|
| Company | Aclaris Therapeutics, INC. (ACRS) |
| Form Type | 8-K |
| Filed Date | Jun 5, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, officer-changes, director-changes
Related Tickers: ACRS
TL;DR
Aclaris Therapeutics (ACRS) filed an 8-K on 6/5/25 detailing director/officer changes and governance updates.
AI Summary
Aclaris Therapeutics, Inc. filed an 8-K on June 5, 2025, reporting on several key events. These include the departure of directors or certain officers, the election of directors, the appointment of certain officers, and updates to compensatory arrangements for certain officers. The filing also covers amendments to articles of incorporation or bylaws, changes in fiscal year, and the submission of matters to a vote of security holders. Additionally, it includes financial statements and exhibits.
Why It Matters
This 8-K filing indicates significant changes in Aclaris Therapeutics' corporate governance and executive structure, which could impact strategic direction and investor confidence.
Risk Assessment
Risk Level: medium — Changes in directors, officers, and compensatory arrangements can signal internal shifts or strategic realignments that may carry inherent business risks.
Key Players & Entities
- Aclaris Therapeutics, Inc. (company) — Registrant
- June 5, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-37581 (identifier) — SEC File Number
- 46-0571712 (identifier) — IRS Employer Identification No.
- 701 Lee Road, Suite 103 Wayne, PA 19087 (address) — Principal executive office address
FAQ
What specific items are covered under the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers' section?
The filing indicates that these items are being reported, but the specific details of who departed, who was elected or appointed, and the nature of the compensatory arrangements are not provided in this summary section of the 8-K.
Are there any amendments to Aclaris Therapeutics' articles of incorporation or bylaws mentioned?
Yes, the filing explicitly lists 'Amendments to Articles of Incorporation or Bylaws' as an item being reported on the Form 8-K.
Does the filing mention any changes to Aclaris Therapeutics' fiscal year?
Yes, 'Change in Fiscal Year' is listed as one of the items covered in this 8-K filing.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is June 5, 2025.
What is the principal executive office address for Aclaris Therapeutics, Inc.?
The principal executive office address is 701 Lee Road, Suite 103, Wayne, PA 19087.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 5, 2025 regarding Aclaris Therapeutics, Inc. (ACRS).